LLY ▲ +0.3% - Eli Lilly and Company
$LLY - Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparison
29-SEP-2026 03:00 AM ET
Share this post
More filings for $LLY
LLY ▼ -1.4% - Eli Lilly and CompanyOct 19, 2026LLY ▲ +0.4% - Eli Lilly and CompanyOct 18, 2026LLY ▲ +3.8% - Eli Lilly and CompanyOct 15, 2026LLY ▲ +1.3% - Eli Lilly and CompanyOct 15, 2026LLY ▲ +3.5% - Eli Lilly and CompanyOct 14, 2026LLY ▼ -0.5% - Eli Lilly and CompanyOct 9, 2026
View full $LLY filing history →💬 Comments
Loading comments…
Leave a comment